Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study

Paul Kwo, Norman Gitlin, Ronald Nahass, David Bernstein, Kyle Etzkorn, Sergio Rojter, Eugene Schiff, Mitchell Davis, Peter Ruane, Ziad Younes, Ronald Kalmeijer, Rekha Sinha, Monika Peeters, Oliver Lenz, Bart Fevery, Guy De La Rosa, Jane Scott, James Witek

Research output: Contribution to journal › Article › peer-review

142 Scopus citations

Fingerprint Dive into the research topics of 'Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study'. Together they form a unique fingerprint.

Medicine & Life Sciences